Friday, December 9, 2016

BRIEF-Astrazeneca says durvalumab gets FDA's priority review status in bladder cancer

* US FDA has accepted first biologics license application

for durvalumab

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)